Anti-Natalizumab ELISA Assay Kit
The Anti-Natalizumab ELISA Assay Kit is For Research Use Only
Size: 12×8 wells
Sensitivity: < 10 ng/mL
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 houurs
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Tysabri
Assay Background
Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn’s disease. It is co-marketed by Biogen and Élan as Tysabri, and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn’s disease. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Natalizumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Natalizumab and may be used for monitoring immunogenicity.
Related Products
Natalizumab ELISA Assay Kit
Anti-Omalizumab (Xolair) ELISA Assay Kit
Anti-Tocilizumab (Actermra) ELISA Assay Kit
